Retatrutide Clinical Trials: Registered Studies and Status
As of November 2, 2026, ClinicalTrials.gov lists 34 registered studies matching Retatrutide or its known aliases as an intervention.
Summary
- Registered studies
- 34
- Most advanced phase
- Phase 3
- Recruiting or not yet recruiting
- 2
- Most recent start
- 2026-02-15
- Most frequent lead sponsor
- Eli Lilly and Company (33)
- Most common status
- Completed
Source: ClinicalTrials.gov, retrieved . Registry searches by name may miss studies that use other identifiers.
Registered studies
| NCT ID | Title | Phase | Status | Enrollment | Start | Lead sponsor |
|---|---|---|---|---|---|---|
| NCT07467447 | Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight | Phase 2 | Recruiting | 300 | 2026-02-15 | Hudson Biotech |
| NCT07357415 | A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Phase 3 | Active not recruiting | 600 | 2026-01-24 | Eli Lilly and Company |
| NCT07232719 | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | Active not recruiting | 250 | 2025-11-17 | Eli Lilly and Company |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Recruiting | 4500 | 2025-10-15 | Eli Lilly and Company |
| NCT06982846 | A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | Phase 1 | Completed | 80 | 2025-06-06 | Eli Lilly and Company |
| NCT06982859 | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Phase 1 | Active not recruiting | 95 | 2025-06-02 | Eli Lilly and Company |
| NCT07035093 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Phase 3 | Active not recruiting | 586 | 2025-05-29 | Eli Lilly and Company |
| NCT06859268 | A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Phase 3 | Active not recruiting | 643 | 2025-03-05 | Eli Lilly and Company |
| NCT06808802 | To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | Phase 1 | Completed | 30 | 2025-02-03 | Eli Lilly and Company |
| NCT06662383 | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Phase 3 | Active not recruiting | 800 | 2024-11-01 | Eli Lilly and Company |
| NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Active not recruiting | 10000 | 2024-04-30 | Eli Lilly and Company |
| NCT06354660 | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | Phase 3 | Completed | 537 | 2024-04-10 | Eli Lilly and Company |
| NCT06313528 | A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | Phase 1 | Completed | 85 | 2024-03-20 | Eli Lilly and Company |
| NCT06297603 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | Phase 3 | Active not recruiting | 320 | 2024-03-15 | Eli Lilly and Company |
| NCT06260722 | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Phase 3 | Active not recruiting | 1250 | 2024-02-21 | Eli Lilly and Company |
| NCT06039826 | A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | Phase 1 | Completed | 46 | 2023-09-12 | Eli Lilly and Company |
| NCT06003465 | A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices | Phase 1 | Completed | 57 | 2023-08-29 | Eli Lilly and Company |
| NCT05931367 | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | Phase 3 | Completed | 445 | 2023-08-01 | Eli Lilly and Company |
| NCT05936151 | A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Phase 2 | Completed | 146 | 2023-07-20 | Eli Lilly and Company |
| NCT05959096 | A Study of LY3437943 in Healthy Participants With a High Body Mass Index | Phase 1 | Completed | 85 | 2023-07-18 | Eli Lilly and Company |
| NCT05916560 | A Study of LY3437943 in Participants With Impaired and Normal Liver Function | Phase 1 | Completed | 43 | 2023-07-13 | Eli Lilly and Company |
| NCT05929079 | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Phase 3 | Completed | 1152 | 2023-07-11 | Eli Lilly and Company |
| NCT05929066 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Phase 3 | Completed | 2335 | 2023-07-10 | Eli Lilly and Company |
| NCT05882045 | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Phase 3 | Completed | 1946 | 2023-05-30 | Eli Lilly and Company |
| NCT05757531 | A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants | Phase 1 | Completed | 7 | 2023-03-17 | Eli Lilly and Company |
| NCT05611957 | A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | Phase 1 | Completed | 29 | 2022-11-16 | Eli Lilly and Company |
| NCT05548231 | A Study of LY3437943 in Chinese Participants With Obesity Or Overweight | Phase 1 | Completed | 32 | 2022-10-24 | Eli Lilly and Company |
| NCT05445232 | A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | Phase 1 | Completed | 32 | 2022-07-08 | Eli Lilly and Company |
| NCT04823208 | A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | 64 | 2021-05-24 | Eli Lilly and Company |
| NCT04881760 | A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | Phase 2 | Completed | 338 | 2021-05-20 | Eli Lilly and Company |
| NCT04867785 | A Study of LY3437943 in Participants With Type 2 Diabetes | Phase 2 | Completed | 281 | 2021-05-13 | Eli Lilly and Company |
| NCT04143802 | A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | 72 | 2019-12-18 | Eli Lilly and Company |
| NCT03841630 | A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants | Phase 1 | Completed | 45 | 2019-03-13 | Eli Lilly and Company |
| NCT07629401 | Pre-approval Expanded Access of Retatrutide (LY3437943) | N/A | Available | — | — | Eli Lilly and Company |
Method and limitations
- Data source: ClinicalTrials.gov API v2, intervention search.
- Query used:
Retatrutide OR LY3437943 - Retrieved: November 2, 2026. Refreshed weekly; changes are reviewed before publication.
- Studies registered only under other names, sponsor codes, or in other registries may be missing.
- A match on name does not mean the study tested this peptide alone; some studies include it as a comparator or combination.
- Status values are reported by sponsors and may be out of date.